Drug shows promise for rare Post-Transplant complication, study cut short
NCT ID NCT03948529
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tested the drug eltrombopag in 9 people who had poor graft function after a stem cell transplant for leukemia. Poor graft function means the new donor cells don't make enough blood cells, leading to low platelets and other issues. The goal was to see if eltrombopag could raise platelet counts and reduce the need for transfusions. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
Conditions
Explore the condition pages connected to this study.